Associated Papers
The shifting landscape of germline RET pathogenic variants with the introduction of panel testing.
Onuma AE et al.
Surgery, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database.
Charoenngam N et al.
European Journal of Endocrinology, 2025
Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.
West CE et al.
Jama Network Open, 2025
Prevalence of the cancer-associated germline variants in Russian adults and long-living individuals: using the ACMG recommendations and computational interpreters for pathogenicity assessment.
Gusakova M et al.
Frontiers in Oncology, 2024
Applications of genomic research in pediatric endocrine diseases.
Kim JH et al.
Clinical and Experimental Pediatrics, 2023
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS et al.
Journal of Personalized Medicine, 2023
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.
Qi XP et al.
Bmc Cancer, 2021
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C et al.
International Journal of Molecular Sciences, 2021
Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study.
Larsen LV et al.
Endocrine Connections, 2020
5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.
Li SY et al.
Frontiers in Endocrinology, 2020
RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.
Qi XP et al.
Thyroid : Official Journal of the American Thyroid Association, 2019
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2019
p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy.
Giacché M et al.
Human Mutation, 2019
Metabolomics signatures of a subset of RET variants according to their oncogenic risk level.
Veyrat-Durebex C et al.
Endocrine-related Cancer, 2019
Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study.
Maciel RMB et al.
Endocrine Connections, 2019
A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.
Martins-Costa MC et al.
Archives of Endocrinology and Metabolism, 2018
Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.
Lebeault M et al.
Thyroid : Official Journal of the American Thyroid Association, 2017
Founder Effect of the RETC611Y Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study.
Mathiesen JS et al.
Thyroid : Official Journal of the American Thyroid Association, 2017
M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
Martins-Costa MC et al.
Endocrine-related Cancer, 2016
Management of hereditary medullary thyroid carcinoma.
Pappa T et al.
Endocrine, 2016
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C et al.
Clinical Endocrinology, 2015
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study.
Lantieri F et al.
International Journal of Cancer, 2013
[Prophylactic thyroidectomy in medullary thyroid cancer].
Peix JL et al.
Bulletin De L'academie Nationale De Medecine, 2012
Development of a low-density DNA microarray for diagnosis of target-site mutations of pyrethroid and organophosphate resistance mutations in the whitefly Bemisia tabaci.
Chung IH et al.
Pest Management Science, 2011
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
Cosci B et al.
Endocrine-related Cancer, 2011
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
Romei C et al.
European Journal of Endocrinology, 2010